Fig. 1 · Structure

Documents & Downloads

DOTA-ECL1i

Cat. No. A59590 CAS 2850189-48-7

CCR2 Inhibitor-DOTA Conjugate

DOTA-ECL1i is a CCR2 inhibitor conjugated with DOTA, designed for use in positron emission tomography (PET) imaging. When radiolabeled with 68Ga, DOTA-ECL1i provides a specific PET tracer that targets CCR2 expression in various pathological conditions. This compound is applicable in research focused on pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, and cancers of the head, neck, and pancreas.

This product is currently unavailable.

Ask us for lead time and price.

Inquire about this product

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 2850189-48-7
Applications CCR2 Inhibitor-DOTA Conjugate
Formula C58H94N14O18S
Molecular Weight 1307.51

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Added to your cart

View Cart Checkout
Loading...